MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-07-2026
INmune Bio Total Shareholders Equity 2011-2026 | INMB
Annual Total Shareholders Equity INmune Bio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.5 M | 32.1 M | 37.3 M | 60.1 M | 80.2 M | 38.8 M | 23.6 M | 16.5 M | 18.1 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 80.2 M | 16.5 M | 36.7 M |
Quarterly Total Shareholders Equity INmune Bio
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.6 M | 25.4 M | 28.9 M | 29.7 M | 32.1 M | 38.7 M | 36.3 M | 28.2 M | 37.3 M | 43.9 M | 50.7 M | 55.3 M | 60.1 M | 63.7 M | 69.9 M | 75.6 M | 80.2 M | 88.3 M | 43.2 M | 63.6 M | 38.8 M | 38.8 M | 38.8 M | 38.8 M | 23.6 M | 23.6 M | 23.6 M | 23.6 M | 16.5 M | 16.5 M | 16.5 M | 16.5 M | 18.1 M | - | - | - | -149 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 88.3 M | -149 K | 38.4 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
5.1 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
789 M | $ 19.14 | 0.74 % | $ 895 M |  USA |
 |
Anika Therapeutics
ANIK
|
212 M | $ 14.74 | -0.2 % | $ 216 M | USA |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K | USA |
 |
Autolus Therapeutics plc
AUTL
|
178 M | $ 1.63 | 3.5 % | $ 434 M |  Britain |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M |  China |
 |
BioNTech SE
BNTX
|
19.2 B | $ 94.9 | 0.82 % | $ 22.9 B | Germany |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B | France |
 |
Athira Pharma
ATHA
|
27.8 M | - | - | $ 269 M | USA |
 |
Esperion Therapeutics
ESPR
|
-302 M | $ 3.13 | -0.48 % | $ 651 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-14.6 M | - | 0.74 % | $ 768 M |  Israel |
 |
Exelixis
EXEL
|
2.16 B | $ 49.35 | 2.47 % | $ 13.4 B | USA |
 |
Fortress Biotech
FBIO
|
49.9 M | $ 2.36 | -1.26 % | $ 65.8 M | USA |
 |
Forte Biosciences
FBRX
|
61 M | $ 24.9 | 3.65 % | $ 322 M | USA |
 |
AbbVie
ABBV
|
-3.27 B | $ 203.32 | 0.97 % | $ 360 B | USA |
 |
Gilead Sciences
GILD
|
22.7 B | $ 133.2 | 1.42 % | $ 166 B | USA |
 |
Compugen Ltd.
CGEN
|
103 M | $ 2.82 | -2.76 % | $ 263 M | Israel |
 |
Checkmate Pharmaceuticals
CMPI
|
69.5 M | - | - | $ 231 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
1.93 B | $ 0.77 | 0.16 % | $ 35.2 M | Israel |
 |
ACADIA Pharmaceuticals
ACAD
|
733 M | $ 22.41 | 0.04 % | $ 3.71 B | USA |
 |
Genprex
GNPX
|
7.96 M | $ 0.85 | -1.99 % | $ 793 K | USA |
 |
Genmab A/S
GMAB
|
36.7 B | $ 26.36 | -0.26 % | $ 1.71 B |  Danmark |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.59 M | $ 3.46 | -1.98 % | $ 5.7 M | Israel |
 |
Grifols, S.A.
GRFS
|
8.61 B | $ 8.05 | -0.62 % | $ 5.47 B |  Spain |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
169 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
78.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
189 M | $ 21.09 | -0.4 % | $ 2.68 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
|
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
16.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Applied Therapeutics
APLT
|
-17.1 M | - | - | $ 8.42 M | USA |